adp-a2m4cd8,afami-cel,nivolumab
adaptimmune therapeutics,bms
['a2m4cd8', 'surpass', 'adp-a2m4', 'solid tumor']
at #esmo22, our dr. david hong presents findings from the surpass trial, evaluating adp-a2m4cd8, a next-generation t cell therapy that targets the mage-a4 cancer antigen, for solid tumors. discover the encouraging early results: #endcancer
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789